MYCN and neuroblastoma: The main finding in this analysis is that on average, integrin αvβ3 was expressed on 68% (95% CI 57%–79%; n = 17) of microvessels in stage 3 MYCN-amplified (high risk) neuroblastomas, but only on 34% (95% CI 26%–42%, n = 34, p < 0.001) of microvessels in MYCN-non-amplified ones (Table 1; Figure 1B).